Literature DB >> 3857233

Clostridium difficile in haematological malignancy.

A Rampling, R E Warren, P C Bevan, C E Hoggarth, D Swirsky, F G Hayhoe.   

Abstract

Twenty patients with haematological malignancies who developed Clostridium difficile bowel infection or colonisation are described. All isolates of C difficile were toxigenic in vitro and faecal cytotoxin (toxin B) was detected in 20/26 episodes. Ten of 20 episodes with detectable faecal cytotoxin were associated with typical antibiotic associated diarrhoea. In the other 10 episodes (nine patients), there was a severe unusual illness which was associated with detection of C difficile. The unusual features of the illness were pronounced jaundice (total bilirubin greater than or equal to 44 mumol/l), abdominal pain and distension, and initial constipation followed either by diarrhoea or by large bowel stasis. Four of these patients died within seven days. Bacteraemia was often a presenting feature in neutropenic patients subsequently shown to have C difficile. This was not the case in non-neutropenic patients. Bacteraemia was commonly polymicrobial and in two cases C difficile was isolated from blood culture. The clinical implications of recognition of this atypical C difficile associated syndrome are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857233      PMCID: PMC499176          DOI: 10.1136/jcp.38.4.445

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  A second relapse of Clostridium difficile colitis.

Authors:  A Rampling; R L Swayne; R E Warren
Journal:  J Antimicrob Chemother       Date:  1981-02       Impact factor: 5.790

2.  Relapse of Clostridium colitis after vancomycin therapy.

Authors:  A Rampling; R E Warren; H V Sykes
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

3.  Neutropenic enterocolitis and Clostridium septicum infection in patients with agranulocytosis.

Authors:  G D Rifkin
Journal:  Arch Intern Med       Date:  1980-06

4.  6-thioguanine as a cause of toxic veno-occlusive disease of the liver.

Authors:  M B Satti; K Weinbren; E C Gordon-Smith
Journal:  J Clin Pathol       Date:  1982-10       Impact factor: 3.411

5.  Pseudomembranous colitis in a leukaemia unit: a report of five fatal cases.

Authors:  D W Milligan; J K Kelly
Journal:  J Clin Pathol       Date:  1979-12       Impact factor: 3.411

6.  Necrotizing colitis in patients with cancer.

Authors:  G M Dosik; M Luna; M Valdivieso; K B McCredie; E A Gehan; B Gil-Extremera; T L Smith; G P Bodey
Journal:  Am J Med       Date:  1979-10       Impact factor: 4.965

7.  Bacteriophage and bacteriocin typing scheme for Clostridium difficile.

Authors:  T L Sell; D R Schaberg; F R Fekety
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

Review 8.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun

9.  Co-trimoxazole for prevention of infection in acute leukaemia.

Authors:  A Enno; D Catovsky; J Darrell; J M Goldman; J Hows; D A Galton
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

10.  Clostridium difficile colitis associated with cancer chemotherapy.

Authors:  M A Cudmore; J Silva; R Fekety; M K Liepman; K H Kim
Journal:  Arch Intern Med       Date:  1982-02
View more
  17 in total

1.  New Clostridium difficile serotypes in Poland.

Authors:  F Meisel-Mikolajczyk; B Sokól
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

2.  Clostridium difficile bacteremia in an immunocompetent child.

Authors:  A Cid; A R Juncal; A Aguilera; B J Regueiro; V González
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

3.  Immunoblotting to demonstrate antigenic and immunogenic differences among nine standard strains of Clostridium difficile.

Authors:  S R Heard; B Rasburn; R C Matthews; S Tabaqchali
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

4.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

5.  Epidemiology and prevention of Clostridium difficile infections in a leukemia unit.

Authors:  M Delmée; B Vandercam; V Avesani; J L Michaux
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

6.  Incidence and significance of Clostridium difficile in hospitalized cancer patients.

Authors:  M Gérard; N Defresne; D Daneau; P Van der Auwera; M Delmée; A M Bourguignon; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

7.  Bacteraemia secondary to pseudomembranous colitis.

Authors:  L Neville; P Noone
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 8.  Polymicrobial septicemia with Clostridium difficile in acute diverticulitis.

Authors:  M Gérard; N Defresne; P Van der Auwera; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

9.  Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains.

Authors:  S R Heard; B Wren; M J Barnett; J M Thomas; S Tabaqchali
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

10.  Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan.

Authors:  Yuan-Pin Hung; Pei-Jane Tsai; Kuei-Hsiang Hung; Hsiu-Chuan Liu; Chih-I Lee; Hsiao-Ju Lin; Yi-Hui Wu; Jiunn-Jong Wu; Wen-Chien Ko
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.